These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 12354469)

  • 1. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study.
    Bergfeldt K; Rydh B; Granath F; Grönberg H; Thalib L; Adami HO; Hall P
    Lancet; 2002 Sep; 360(9337):891-4. PubMed ID: 12354469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
    Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
    J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
    Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
    N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of cancer after use of fertility drugs with in-vitro fertilisation.
    Venn A; Watson L; Bruinsma F; Giles G; Healy D
    Lancet; 1999 Nov; 354(9190):1586-90. PubMed ID: 10560672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer risk in close relatives of women with early-onset breast cancer--a population-based incidence study.
    Olsen JH; Seersholm N; Boice JD; Krüger Kjaer S; Fraumeni JF
    Br J Cancer; 1999 Feb; 79(3-4):673-9. PubMed ID: 10027348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer prognosis in relation to family history of breast and ovarian cancer.
    Thalib L; Wedrén S; Granath F; Adami HO; Rydh B; Magnusson C; Hall P
    Br J Cancer; 2004 Apr; 90(7):1378-81. PubMed ID: 15054458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genetic attributable risk of breast and ovarian cancer.
    Claus EB; Schildkraut JM; Thompson WD; Risch NJ
    Cancer; 1996 Jun; 77(11):2318-24. PubMed ID: 8635102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Family history of breast and ovarian cancer among breast-cancer patients in the Connecticut Tumor Registry.
    Polednak AP; Flannery JT
    Conn Med; 1996 Feb; 60(2):67-73. PubMed ID: 8820629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial breast and ovarian cancer: a Swedish population-based register study.
    Anderson H; Bladström A; Olsson H; Möller TR
    Am J Epidemiol; 2000 Dec; 152(12):1154-63. PubMed ID: 11130621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population prevalence of first- and second-degree family history of breast and ovarian cancer.
    Moghimi-Dehkordi B; Safaee A; Vahedi M; Pourhoseingholi MA; Pourhoseingholi A; Zali MR
    East Afr J Public Health; 2011 Dec; 8(4):275-7. PubMed ID: 23120936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
    Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
    J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial clustering of colon, breast, uterine, and ovarian cancers as assessed by family history.
    Nelson CL; Sellers TA; Rich SS; Potter JD; McGovern PG; Kushi LH
    Genet Epidemiol; 1993; 10(4):235-44. PubMed ID: 8224804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.